Birkerød, Denmark

Ingun Christiansen



Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ingun Christiansen: Innovator in Peptide Stabilization

Introduction

Ingun Christiansen, a talented inventor based in Birkerød, Denmark, has made significant contributions to the field of biochemical research. With a focus on the stabilization of peptides, polypeptides, and proteins, her work has implications for diverse applications in pharmaceuticals and biotechnology.

Latest Patents

Christiansen holds a patent titled "Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins." This innovative approach addresses the challenges of gelation, fibrillation, and aggregation that can occur during the processing and purification of various peptide analogs, including Glucagon-Like Peptides (GLPs). Her method incorporates tris(hydroxymethyl)aminomethane to enhance the stability of these crucial biological molecules, proving invaluable for downstream processing.

Career Highlights

Ingun Christiansen is currently affiliated with Novo Nordisk A/S, a global leader in diabetes care and biopharmaceutical innovations. Her role within the company allows her to pursue groundbreaking research that aligns with Novo Nordisk's dedication to improving healthcare outcomes.

Collaborations

Christiansen collaborates with her esteemed coworker, Arne Staby, bringing together their expertise to further the development and application of stabilizing methods for peptides and proteins. This partnership fosters an environment of creativity and innovation, essential for advancing research in their field.

Conclusion

Ingun Christiansen exemplifies the role of a dedicated inventor in the biotechnology sector. Her patented method for stabilizing peptides contributes to the scientific community's understanding of protein stability, paving the way for future innovations. As she continues her work at Novo Nordisk A/S, her endeavors will likely lead to further advancements in pharmaceuticals and biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…